Goldsmith_EU_Renal 9/7/07 9:53 am Page 43
Direct Renin Inhibitors – Nuance or Necessity?
In six patients with renal dysfunction, a short-acting renin inhibitor – Finally, other DRIs are expected to join aliskiren in clinical use in the years
remikiren – reduced proteinuria by 27% (range -18 to -38%; p<0.01) to come, seeing that some of these new agents are currently undergoing
from a median baseline level of 5.8g/day.
41
Preliminary data from an animal and pre-clinical investigation.
30
ongoing clinical study indicate a more substantial reduction in
microalbuminuria with aliskiren (-61%) compared with ramipril (-50%).
45
DRIs may have a future as renoprotective agents besides their
antihypertensive usefulness, but at the moment it is much too early to be
Conclusion more than just interested in this class of agent. Crucially, this type of drug
In the next few years, the results of the first phase III trials with aliskiren needs to be able to demonstrate not only BP-lowering effects, which are
in patients with CKD will become available. The ongoing Aliskiren in the useful for all patients with chronic kidney disease, but also an ability to
Evaluation of Proteinuria in Diabetes (AVOID) study is a six-month study reduce proteinuria at least to the extent predicted by BP fall. The ability
of aliskiren in addition to losartan in 496 patients with controlled to decrease renin concentration and PRA, the more complete inhibition
hypertension, type 2 diabetes and proteinuria. The primary end-point is of the RAAS, the expected limitation of Ang II and aldosterone escape
the urinary albumin to creatinine ratio. Aliskiren Trial in Type 2 Diabetic phenomena and the prevention of possible renal-damaging direct effects
Nephropathy (ALTITUDE) is a type 2 diabetes outcomes study that will be of renin make aliskiren an appealing drug for nephrologists once the
carried out in approximately 6,000 subjects to determine whether pivotal information about change in plasma potassium, urinary protein
aliskiren delays time to diabetic complications in patients with diabetes and the GFR of patients is known in cohorts representative of the typical
mellitus and nephropathy.
45
older renal patients. ■
1. Rüster C, Wolf G, Renin-angiotensin-aldosterone system and 15. Van de Wal RM, Plokker HW, Lok DJ, et al., Determinants of chronic kidney disease, Kidney Int, 2006;70(11):1905–13.
progression of renal disease, J Am Soc Nephrol, 2006;17: increased angiotensin II levels in severe chronic heart failure 32. Gradman AH, Schmieder RE, Lins RL, et al., Aliskiren, a novel
2985–91. patients despite ACE inhibition, Int J Cardiol, 2006;106: orally effective renin inhibitor, provides dose-dependent
2. Nishiyama A, Abe Y, Molecular mechanisms and therapeutic 367–72. antihypertensive efficacy and placebo-like tolerability in
strategies of chronic renal injury: Renoprotective effects of 16. Nguyen G, Delarue F, Burckle C, et al., Pivotal role of the hypertensive patients, Circulation, 2005;111:1012–18.
aldosterone blockade, J Pharmacol Sci, 2006;100:9–16. renin/prorenin receptor in angiotensin II production and cellular 33. Villamil A, Chrysant S, Calhoun D, et al., The novel oral renin
3. Lewis EJ, Hunsicker LG, Bain RP, et al., The effect of responses to renin, J Clin Invest, 2002;10:1417–27. inhibitor aliskiren provides effective blood pressure control in
angiotensin converting-enzyme inhibition on diabetic 17. Hamming I, Navis G, Kocks MJ, van Goor H, ACE inhibition has patients with hypertension when used alone or in combination
nephropathy: The Collaborative Study Group, N Engl J Med, adverse renal effects during dietary sodium restriction in with hydrochlorothiazide, J Clin Hypertens, 2006;8(5 Suppl. A):
1993;329:1456–62. proteinuric and healthy rats, J Pathol, 2006;209:129–39. P-228.
4. Brenner BM, Cooper ME, De Zeeuw D, et al., for the RENAAL 18. Cicoira M, Zanolla L, Rossi A, et al., Failure of aldosterone 34. Uresin Y, Taylor A, Kilo C, et al., Aliskiren, a novel renin
Study Investigators, Effects of losartan on renal and suppression despite angiotensin-converting enzyme (ACE) inhibitor, has greater BP lowering than ramipril and additional
cardiovascular outcomes in patients with type 2 diabetes and inhibitor administration in chronic heart failure is associated BP lowering when combined with ramipril in patients with
nephropathy, N Engl J Med, 2001;345:861–9. with ACE DD genotype, J Am Coll Cardiol, 2001;37:1808–12. diabetes and hypertension, J Hypertens, 2006;24(suppl 4):S82.
5. Lewis EJ, Hunsicker LG, Clarke WR, et al., Renoprotective effect 19. Struthers AD, Aldosterone blockade in cardiovascular disease, 35. Munger MA, Drummond W, Essop MR, et al., Aliskiren as add-
of the angiotensin-receptor antagonist irbesartan in patients Heart, 2004;90:1229–34. on to amlodipine provides significant additional blood pressure
with nephropathy due to type 2 diabetes, N Engl J Med, 20. Naruse M, Tanabe A, Sato A, et al., Aldosterone breakthrough lowering without increased oedema associated with doubling
2001;345:851–60. during angiotensin II receptor antagonist therapy in stroke- the amlodipine dose. Abstract presented at WCC/ESC,
6. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in prone spontaneously hypertensive rats, Hypertension, 2002;40: Barcelona, Spain, 2–6 September 2006 (P784).
Nefrologia), Randomised placebo-controlled trial of effect of 28–33. 36. Pool JL, Schmieder RE, Azizi M, et al., Aliskiren, an orally
ramipril on decline in glomerular filtration rate and risk of 21. Ruiz-Ortega M, Ruperez M, Esteban V, et al., Angiotensin II: a effective rennin inhibitor, provides antihypertensive efficacy
terminal renal failure in proteinuric, non-diabetic nephropathy, key factor in the inflammatory and fibrotic response in kidney alone and in combination with valsartan, Am J Hypertens,
Lancet, 1997;349:1857–63. diseases, Nephrol Dial Transplant, 2006;21(1):16–20. 2007;20:11–20.
7. Wright JT, Bakris G, Greene T, et al., Effect of blood pressure 22. Nussberger J, Wuerzner G, Jensen C, Brunner HR, Angiotensin 37. Clozel JP, Veniant MM, Qiu C, et al., Renal vascular and
lowering and antihypertensive drug class on progression of II suppression in humans by the orally active renin inhibitor biochemical responses to systemic rennin inhibition in dogs at
hypertensive kidney disease: Results from the AASK trial, JAMA, aliskiren (SPP100). Comparison with enalapril, Hypertension, low renal perfusion pressure, J Cardiovasc Pharmacol, 1999;34:
2002;288:2421–31. 2002;39:e1–e8. 674–82.
8. Maschio G, Alberti D, Janin G, et al., Effect of the angiotensin- 23. Tekturna (aliskiren). Prescribing information. Available at: 38. Verburg KM, Kleinert HD, Chekal MA, et al., Renal
converting-enzyme inhibitor benazepril on the progression of http://www.fda.gov hemodynamic and excretory responses to renin inhibition
chronic renal insufficiency (The Angiotensin-Converting-Enzyme 24. Mitchell J, Oh B, Herron J, et al., Once-daily aliskiren provides induced by A-64662, J Pharmacol Exp Ther, 1990;252:449–55.
Inhibition in Progressive Renal Insufficiency Study Group), effective, smooth 24-hour blood pressure control in patients 39. El Amrani AIK, Ménard J, Gonzales MF, Michel JB, Effects of
N Engl J Med, 1996;334:939–45. with hypertension, J Clin Hypertens, 2006;8(5 suppl. A):A93 blocking the angiotensin II receptor, converting enzyme, and
9. Griffin KA, bu-Amarah I, Picken M, et al., Renoprotection by (P-209). Poster presented at ASH 2006. rennin activity on the renal hemodynamics of normotensive
ACE inhibition or aldosterone blockade is blood pressure- 25. Feldman DL, Persohn E, Schutz H, et al., Renal localization of Guinea pigs, J Cardiovasc Pharmacol, 1993;22:231–9.
dependent, Hypertension, 2003;41:201–6. the renin inhibitor aliskiren, J Clin Hypertens, 2006;8(Suppl. A): 40. Fisher NDL, Allan D, Kifor I, et al., Responses to converting
10. UK Prospective Diabetes Study Group, Efficacy of atenolol and A80. enzyme and renin inhibition: role of angiotensin II in humans,
captopril in reducing risk of macrovascular and microvascular 26. Phillips MI, Speakman EA, Kimura B, Levels of angiotensin and Hypertension, 1994;23:44–51.
complications in type 2 diabetes: UKPDS 39, BMJ, 1998;317: molecular biology of the tissue renin angiotensin systems, Regul 41. van Paassen P, de Zeeuw D, Navis G, de Jong PE, Renal and
713–20. Pept, 1993;43:1–20. systemic effects of continued treatment with renin inhibitor
11. Rahman M, Pressel S, Davis BR, et al., Renal outcomes in 27. Fisher NDL, Hollenberg NK, Renin inhibition: what are the remikiren in hypertensive patients with normal and impaired
high-risk hypertensive patients treated with an angiotensin- therapeutic opportunities?, J Am Soc Nephrol, 2005;16:592–9. renal function, Nephrol Dial Transplant, 2000;15:637–43.
converting enzyme inhibitor or a calcium channel blocker vs a 28. O’Brien E, Barton J, Nussberger J, et al., Aliskiren reduces blood 42. Pilz B, Shagdarsuren E, Wellner M, et al., Aliskiren, a human
diuretic: A report from the Antihypertensive and Lipid-Lowering pressure and suppresses plasma renin activity in combination renin inhibitor, ameliorates cardiac and renal damage in
Treatment to Prevent Heart Attack Trial (ALLHAT), Arch Intern with a thiazide diuretic, an angiotensin-converting enzyme double-transgenic rats, Hypertension, 2005;46(3):569–76.
Med, 2005;165:936–46. inhibitor, or an angiotensin receptor blocker, Hypertension, 43. Feldman D, Jin L, Miserindinomoltini R, et al., Aliskiren, a
12. Casas JP, Chua W, Loukogeorgakis S, et al., Effect of 2007;49(2):276–84. human renin inhibitor induces persistent renoprotection
inhibitors of the renin-angiotensin system and other 29. Athyros VG, Mikhailidis DP, Kakafika AI, et al., Angiotensin II comparable to ACE inhibition in double transgenic rats (dTGR),
antihypertensive drugs on renal outcomes: Systematic review reactivation and aldosterone escape phenomena in renin- Am J Hypertens, 2005;18(5):A230–A230.
and meta-analysis, Lancet, 2005;366:2026–33. angiotensin-aldosterone system blockade: is oral renin 44. Shagdarsuren E, Wellner M, Braesen JH, et al., Complement
13. Sarafidis PA, Khosla N, Bakris GL, Antihypertensive therapy in inhibition the solution?, Expert Opin Pharmacother, 2007;8(5): activation in angiotensin II-induced organ damage, Circ Res,
the presence of proteinuria, Am J Kidney Dis, 2007;49(1): 529–35. 2005;97(7):716–24.
12–26. 30. Staessen JA, Li Y, Richart T, Oral renin inhibitors, Lancet, 45. Chris Jensen J, SPP100 (Aliskiren), The journey from the
14. Hollenberg NK, Fisher NDL, Renal circulation and blockade of 2006;368(9545):1449–56. laboratory bench to market. Available at: www.speedel.com
the renin-angiotensin system, Hypertension, 1995;26:602–9. 31. Bakris GL, Hart P, Ritz E, Beta blockers in the management of
EUROPEAN RENAL DISEASE 2007 43
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74